Vistagen Therapeutics Gains Momentum; Blend Labs Beats Estimates
- August 10th, 2023
- 403 views
Shares of Vistagen Therapeutics, Inc. (Nasdaq: VTGN) surged over 20% in after-hours trading as Commodore Capital LP disclosed in a regulatory filing (Form 4) with the SEC that it has recently acquired 775,756 shares of Vistagen through multiple transactions, at an average price of $23.153 per share.
The late clinical-stage biopharmaceutical company will be reporting its first-quarter fiscal-year 2024 financial results after the market closes on Thursday, August 10.
$VTGN was trading at $8.65 in after-hours, reflecting a significant increase of $1.61 or 22.96%.
In other news, Blend Labs, Inc. (NYSE: BLND) reported better-than-expected second-quarter 2023 financial results. The company's loss per share came in at $(0.09), outperforming the consensus estimate loss of $(0.13). In addition, Blend Labs achieved quarterly sales of $42.81 million, surpassing analysts' projected revenue of $40.11 million for the period.
In after-hours, $BLND was trading at $1.46, up $0.24 (+19.67%)
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
December 05th, 2025
FDA Approves Nerve Scaffold for the Treatment of Sensory Nerve Discontinuity
December 04th, 2025December 02nd, 2025Earnings Countdown: Salesforce, Snowflake, and Guidewire Take Center Stage
November 30th, 2025Wall Street Eyes CrowdStrike, Marvell Technology, and GitLab as Earnings Near
November 30th, 2025
Member Login